News Center
The influence of the LIZHU brand has won acclaim.
Release time:
2016-04-25
On April 22, the Zhuhai Federation of Industry and Commerce held an exchange meeting with the Jilin Federation of Industry and Commerce at the Zhuhai Federation of Industry and Commerce building. As a star enterprise that has grown locally in Zhuhai, Lijuzhu Group was invited to attend the meeting. Editor-in-Chief Liu Xibin of New Lijuzhu attended the meeting and delivered a speech on "Four Advantages Continuously Refreshing the Lijuzhu Brand Influence." Yang Hongmei, Vice Chairman of the Zhuhai Federation of Industry and Commerce and Zhuhai General Chamber of Commerce, Jiang Chunhong, Deputy Minister of the Jinwan United Front Work Department and Secretary of the Federation of Industry and Commerce Party Group, Huang Jinye, Vice Chairman of the Xiangzhou District Federation of Industry and Commerce, and nearly 30 guests and friends from the visiting Jilin Federation of Industry and Commerce attended the meeting for exchange. Editor-in-Chief Liu first represented the enterprises of Zhuhai and Lijuzhu Group.
On April 22, the Zhuhai Federation of Industry and Commerce and the Jilin Federation of Industry and Commerce held an exchange meeting at the Zhuhai Federation of Industry and Commerce building. Lijun Group, as a star enterprise grown locally in Zhuhai, was invited to attend the meeting. The chief editor of New Lijun, Liu Xibin, attended the meeting and delivered a speech on "Four Advantages Continuously Refreshing the Influence of the Lijun Brand." Yang Hongmei, Vice Chairman of the Zhuhai Federation of Industry and Commerce, Jiang Chunhong, Deputy Minister of the Jinwan United Front Work Department and Secretary of the Federation of Industry and Commerce, Huang Jinye, Vice Chairman of the Xiangzhou District Federation of Industry and Commerce, and nearly 30 guests and friends from the Jilin Federation of Industry and Commerce attended the meeting for exchange.
Editor Liu first welcomed the guests from the Jilin Federation of Industry and Commerce to Zhuhai on behalf of Zhuhai enterprises and Lijun Group. He said: Lijun is a local enterprise in Zhuhai that has grown up in the tide of reform and opening up. After more than 30 years of exploration and progress, it has grown into a nationally influential pharmaceutical enterprise. The 30-year development of Lijun is a process of continuous accumulation and sublimation of the Lijun brand. If we compare Lijun Group to a big tree, then the many products are the "branches." Today, this big tree of Lijun Group is lush and has formed four unique advantages: First, R&D advantage, with three national-level and four provincial-level R&D centers. Second, brand advantage, with more than 10 brand products including Lijun Dele, a number of intellectual property achievements, and 110 patent authorizations, including: 94 domestic invention patents; 16 international patents; the injection of Ginseng and Astragalus and Aplrazole have successively won the first prize for scientific and technological progress in Guangdong Province; antiviral granules won the first prize for scientific and technological progress from the Chinese Medical Association; the original new drug Aplrazole also won the second prize for national scientific and technological progress. Third, quality advantage, taking the lead in implementing quality (laboratory) management systems nationwide, with all 56 production lines of the group passing the new version of GMP certification, and 5 raw materials passing the US FDA certification, 4 passing the EU COS certification. Fourth, capital market platform advantage, in 1993, Lijun was listed on both A and B shares, becoming the first company in the pharmaceutical industry to be listed on both A and B shares simultaneously; in January 2014, Lijun successfully transitioned from B shares to H shares and was listed on the Hong Kong Stock Exchange, becoming the first pharmaceutical company to complete the B to H transition. In recent years, Lijun has entered the field of biopharmaceutical R&D, with monoclonal antibody products entering the clinical stage, expected to be launched in the market in 3 years; in 2015, Lijun began to layout precision medicine, and this year officially established Shengmei Diagnostic Technology Co., Ltd., placing Lijun at the forefront of global medical technology.
The development of Lijun is the result of the hard work of all Lijun people, and it has also received careful care and love from the general public and users, as well as the support and protection from local governments and democratic parties and groups, including the Federation of Industry and Commerce. Lijun is still on the road, let us walk hand in hand!
Editor Liu's wonderful speech and the story of the Lijun brand won warm applause from the industry and commerce representatives from both places, who then inquired about the relevant situation of Lijun's brand operation.
Related Information